Inhibiting the redox-sensitive transcription factor NF-κB is also an essential therapy targeting inflammation in MASLD to prevent the progression to worse disease stages such as MASH [19]. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.